Titre : Intégrine alpha2

Intégrine alpha2 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Clinical Decision-Making
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Intégrine alpha2 : Questions médicales les plus fréquentes", "headline": "Intégrine alpha2 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Intégrine alpha2 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-17", "dateModified": "2025-04-13", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Intégrine alpha2" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Intégrines alpha", "url": "https://questionsmedicales.fr/mesh/D039001", "about": { "@type": "MedicalCondition", "name": "Intégrines alpha", "code": { "@type": "MedicalCode", "code": "D039001", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.705.408.100" } } }, "about": { "@type": "MedicalCondition", "name": "Intégrine alpha2", "alternateName": "Integrin alpha2", "code": { "@type": "MedicalCode", "code": "D039421", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Evgenia Sitnikova", "url": "https://questionsmedicales.fr/author/Evgenia%20Sitnikova", "affiliation": { "@type": "Organization", "name": "Institute of the Higher Nervous Activity and Neurophysiology of Russian Academy of Sciences, Butlerova Str., 5A, Moscow 117485, Russia." } }, { "@type": "Person", "name": "Elizaveta Rutskova", "url": "https://questionsmedicales.fr/author/Elizaveta%20Rutskova", "affiliation": { "@type": "Organization", "name": "Institute of the Higher Nervous Activity and Neurophysiology of Russian Academy of Sciences, Butlerova Str., 5A, Moscow 117485, Russia." } }, { "@type": "Person", "name": "Jia Liu", "url": "https://questionsmedicales.fr/author/Jia%20Liu", "affiliation": { "@type": "Organization", "name": "Shenzhen Jiake Biotechnology, Shenzhen, China." } }, { "@type": "Person", "name": "Michael Bachmann", "url": "https://questionsmedicales.fr/author/Michael%20Bachmann", "affiliation": { "@type": "Organization", "name": "Department of Cell Physiology and Metabolism, University of Geneva, Centre Médical Universitaire, Rue Michel-Servet 1, 1211 Geneva 4, Switzerland." } }, { "@type": "Person", "name": "Vesa P Hytönen", "url": "https://questionsmedicales.fr/author/Vesa%20P%20Hyt%C3%B6nen", "affiliation": { "@type": "Organization", "name": "Faculty of Medicine and Health Technology, Tampere University, Arvo Ylpön katu 34, FI-33520 Tampere, Finland." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Use of a Novel Clinical Decision-Making Tool in Vestibular Schwannoma Treatment.", "datePublished": "2022-10-14", "url": "https://questionsmedicales.fr/article/36240736", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/MAO.0000000000003719" } }, { "@type": "ScholarlyArticle", "name": "The influence of defaecating proctograms on clinical decision-making in pelvic floor disorders.", "datePublished": "2023-08-15", "url": "https://questionsmedicales.fr/article/37583050", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/codi.16706" } }, { "@type": "ScholarlyArticle", "name": "Examining the impact of virtual reality on clinical decision making - An integrative review.", "datePublished": "2023-02-27", "url": "https://questionsmedicales.fr/article/36906980", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.nedt.2023.105767" } }, { "@type": "ScholarlyArticle", "name": "Restorative dentistry clinical decision-making for hypodontia: retained primary molars.", "datePublished": "2023-10-13", "url": "https://questionsmedicales.fr/article/37828179", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41415-023-6318-3" } }, { "@type": "ScholarlyArticle", "name": "Nursing Students' Fear of Negative Evaluation and Perceptions of Clinical Decision-Making.", "datePublished": "2023-06-01", "url": "https://questionsmedicales.fr/article/37279974", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3928/01484834-20221011-02" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines membranaires", "item": "https://questionsmedicales.fr/mesh/D008565" }, { "@type": "ListItem", "position": 5, "name": "Récepteurs de surface cellulaire", "item": "https://questionsmedicales.fr/mesh/D011956" }, { "@type": "ListItem", "position": 6, "name": "Récepteurs immunologiques", "item": "https://questionsmedicales.fr/mesh/D011971" }, { "@type": "ListItem", "position": 7, "name": "Intégrines", "item": "https://questionsmedicales.fr/mesh/D016023" }, { "@type": "ListItem", "position": 8, "name": "Intégrines alpha", "item": "https://questionsmedicales.fr/mesh/D039001" }, { "@type": "ListItem", "position": 9, "name": "Intégrine alpha2", "item": "https://questionsmedicales.fr/mesh/D039421" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Intégrine alpha2 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Intégrine alpha2", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-08", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Intégrine alpha2", "description": "Comment diagnostiquer une anomalie d'intégrine alpha2 ?\nQuels examens sont recommandés pour l'intégrine alpha2 ?\nQuels marqueurs biologiques sont associés à l'intégrine alpha2 ?\nL'imagerie est-elle utile pour l'intégrine alpha2 ?\nPeut-on détecter l'intégrine alpha2 dans le sang ?", "url": "https://questionsmedicales.fr/mesh/D039421?mesh_terms=Clinical+Decision-Making&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Intégrine alpha2", "description": "Quels symptômes sont liés à une déficience d'intégrine alpha2 ?\nL'intégrine alpha2 affecte-t-elle la peau ?\nY a-t-il des symptômes systémiques associés ?\nComment l'intégrine alpha2 influence-t-elle l'inflammation ?\nDes douleurs articulaires peuvent-elles être liées à l'intégrine alpha2 ?", "url": "https://questionsmedicales.fr/mesh/D039421?mesh_terms=Clinical+Decision-Making&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Intégrine alpha2", "description": "Comment prévenir les troubles liés à l'intégrine alpha2 ?\nY a-t-il des tests de dépistage recommandés ?\nL'exercice physique joue-t-il un rôle préventif ?\nLes vaccinations sont-elles importantes ?\nLe stress a-t-il un impact sur l'intégrine alpha2 ?", "url": "https://questionsmedicales.fr/mesh/D039421?mesh_terms=Clinical+Decision-Making&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Intégrine alpha2", "description": "Quels traitements sont disponibles pour les anomalies d'intégrine alpha2 ?\nLa thérapie génique est-elle une option ?\nDes médicaments spécifiques ciblent-ils l'intégrine alpha2 ?\nComment la physiothérapie aide-t-elle ?\nLes traitements sont-ils personnalisés ?", "url": "https://questionsmedicales.fr/mesh/D039421?mesh_terms=Clinical+Decision-Making&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Intégrine alpha2", "description": "Quelles complications peuvent survenir avec une anomalie d'intégrine alpha2 ?\nL'intégrine alpha2 est-elle liée à des maladies auto-immunes ?\nDes complications cardiovasculaires sont-elles possibles ?\nComment les complications affectent-elles la qualité de vie ?\nLes complications sont-elles réversibles ?", "url": "https://questionsmedicales.fr/mesh/D039421?mesh_terms=Clinical+Decision-Making&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Intégrine alpha2", "description": "Quels sont les facteurs de risque pour les troubles d'intégrine alpha2 ?\nL'âge influence-t-il le risque d'anomalies ?\nLe mode de vie affecte-t-il le risque ?\nLes infections antérieures sont-elles un facteur de risque ?\nLe tabagisme influence-t-il le risque ?", "url": "https://questionsmedicales.fr/mesh/D039421?mesh_terms=Clinical+Decision-Making&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une anomalie d'intégrine alpha2 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses de sang peuvent être utilisés pour diagnostiquer des anomalies." } }, { "@type": "Question", "name": "Quels examens sont recommandés pour l'intégrine alpha2 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des biopsies et des tests d'adhésion cellulaire peuvent être effectués pour évaluer l'intégrine alpha2." } }, { "@type": "Question", "name": "Quels marqueurs biologiques sont associés à l'intégrine alpha2 ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les marqueurs comme les cytokines et les facteurs de croissance peuvent être évalués." } }, { "@type": "Question", "name": "L'imagerie est-elle utile pour l'intégrine alpha2 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie n'est pas directement utilisée, mais peut aider à évaluer les tissus affectés." } }, { "@type": "Question", "name": "Peut-on détecter l'intégrine alpha2 dans le sang ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des tests sanguins peuvent mesurer les niveaux d'intégrine alpha2 circulante." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une déficience d'intégrine alpha2 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des problèmes de cicatrisation et des troubles immunitaires." } }, { "@type": "Question", "name": "L'intégrine alpha2 affecte-t-elle la peau ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une déficience peut entraîner des lésions cutanées et une mauvaise cicatrisation." } }, { "@type": "Question", "name": "Y a-t-il des symptômes systémiques associés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes systémiques comme la fatigue et des infections récurrentes peuvent survenir." } }, { "@type": "Question", "name": "Comment l'intégrine alpha2 influence-t-elle l'inflammation ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Elle régule l'inflammation, et une anomalie peut entraîner une inflammation excessive." } }, { "@type": "Question", "name": "Des douleurs articulaires peuvent-elles être liées à l'intégrine alpha2 ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des douleurs articulaires peuvent survenir en raison de l'inflammation associée." } }, { "@type": "Question", "name": "Comment prévenir les troubles liés à l'intégrine alpha2 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et un mode de vie sain peuvent aider à prévenir les troubles." } }, { "@type": "Question", "name": "Y a-t-il des tests de dépistage recommandés ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques peuvent être recommandés pour les personnes à risque familial." } }, { "@type": "Question", "name": "L'exercice physique joue-t-il un rôle préventif ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut améliorer la santé cellulaire et réduire les risques." } }, { "@type": "Question", "name": "Les vaccinations sont-elles importantes ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les vaccinations peuvent prévenir les infections qui aggravent les troubles immunitaires." } }, { "@type": "Question", "name": "Le stress a-t-il un impact sur l'intégrine alpha2 ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress peut affecter la fonction immunitaire et l'expression de l'intégrine alpha2." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour les anomalies d'intégrine alpha2 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des thérapies immunomodulatrices et des soins de soutien." } }, { "@type": "Question", "name": "La thérapie génique est-elle une option ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la thérapie génique est explorée pour corriger les anomalies d'intégrine alpha2." } }, { "@type": "Question", "name": "Des médicaments spécifiques ciblent-ils l'intégrine alpha2 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des inhibiteurs de l'intégrine alpha2 sont en développement pour traiter certaines maladies." } }, { "@type": "Question", "name": "Comment la physiothérapie aide-t-elle ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "La physiothérapie peut améliorer la fonction et réduire la douleur associée aux troubles." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements peuvent être adaptés en fonction des besoins individuels du patient." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec une anomalie d'intégrine alpha2 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des infections récurrentes et des problèmes de cicatrisation." } }, { "@type": "Question", "name": "L'intégrine alpha2 est-elle liée à des maladies auto-immunes ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anomalies peuvent augmenter le risque de maladies auto-immunes." } }, { "@type": "Question", "name": "Des complications cardiovasculaires sont-elles possibles ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles d'adhésion cellulaire peuvent contribuer à des problèmes cardiovasculaires." } }, { "@type": "Question", "name": "Comment les complications affectent-elles la qualité de vie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Les complications peuvent réduire la qualité de vie en limitant les activités quotidiennes." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les troubles d'intégrine alpha2 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux, des maladies auto-immunes et le stress." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque d'anomalies ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque d'anomalies d'intégrine alpha2 peut augmenter avec l'âge." } }, { "@type": "Question", "name": "Le mode de vie affecte-t-il le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque." } }, { "@type": "Question", "name": "Les infections antérieures sont-elles un facteur de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des infections chroniques peuvent prédisposer à des troubles d'intégrine alpha2." } }, { "@type": "Question", "name": "Le tabagisme influence-t-il le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut affecter la fonction immunitaire et augmenter le risque." } } ] } ] }

Sources (10000 au total)

Use of a Novel Clinical Decision-Making Tool in Vestibular Schwannoma Treatment.

To determine the usefulness of a personalized tool and its effect on the decision-making process for those with vestibular schwannoma (VS).... Prospective study.... Single institution, academic tertiary care lateral skull base surgery program.... Patients diagnosed with VS.... A comprehensive clinical decision support (CDS) tool was constructed from a previously published retrospective patient-reported data obtained from members of the Acoustic Neuroma Association from Janu... Pre- and posttool questionnaires assessing the process of deciding treatment for VS using a decisional conflict scale (DCS) and satisfaction with decision (SWD) scale were compared.... A pilot study of 33 patients evaluated at a single institution tertiary care center with mean ± SD age of 63.9 ± 13.5 years and with average tumor size of 7.11 ± 4.75 mm were surveyed. CDS implementat... Implementing a decision-making tool after diagnosis of VS reduced decisional conflict and improved satisfaction with decision. Patients considered the tool to be an aid to their medical knowledge, fur...

The influence of defaecating proctograms on clinical decision-making in pelvic floor disorders.

Defaecating proctogram (DP) studies have become an integral part of the evaluation of patients with pelvic floor disorders. However, their impact on treatment decision-making remains unclear. The aim ... Four colorectal surgeons were presented with online surveys containing the complete history, examination and investigations of 106 de-identified pelvic floor patients who had received one of three tre... After the addition of the DP results; treatment choice changed in 219 (52%) of 424 surgical decisions and interrater agreement improved significantly from κ = 0.26 to κ = 0.39. Three of the four surge... The DP improves interclinician agreement in the management of pelvic floor disorders and enhances the confidence in treatment decisions. Intra-anal rectal prolapse was the most influential DP paramete...

Examining the impact of virtual reality on clinical decision making - An integrative review.

Clinical decision making is an essential cognitive skill in nursing. It is a process undertaken daily by nurses as they make judgements about patient care and manage complex issues as they arise. Virt... The objective of this integrative review are to synthesise the research findings regarding the impact of virtual reality on clinical decision making in undergraduate nurses.... An integrative review using Whittemore and Knafl's framework for integrated reviews.... An extensive search was conducted of healthcare databases including CINAHL, Medline and Web of Science between 2010 and 2021 using the terms virtual reality, clinical decision and undergraduate nursin... The initial search located 98 articles. After screening and checking for eligibility, 70 articles were critically reviewed. Eighteen studies were included in the review and were critically appraised u... Research in the use of VR has demonstrated its potential to improve undergraduate nurses' critical thinking, clinical reasoning, clinical judgement and clinical decision-making skills. Students percei... Current research on the impact of virtual reality on the development of nursing CDM has demonstrated positive results. VR is one pedagogical approach that could further assist, however, there are no i...

Nursing Students' Fear of Negative Evaluation and Perceptions of Clinical Decision-Making.

Nursing is a profession based on theoretical knowledge and practice, and the clinical decision-making process is important. Many factors affect the fear of negative evaluation, and fear of a negative ... This descriptive cross-sectional study included undergraduate nursing students (... Nursing students' fear of a negative evaluation and clinical decision-making scale scores were 31.92 ± 08.51 and 149.18 ± 13.67, respectively. No significant relationship was identified between the sc... The fear of a negative evaluation was not associated with nursing students' perceptions of clinical decision-making. To reduce nursing students' fear of a negative evaluation and improve their clinica...

Clinical decision making under uncertainty: a bootstrapped counterfactual inference approach.

Learning policies for decision-making, such as recommending treatments in clinical settings, is important for enhancing clinical decision-support systems. However, the challenge lies in accurately eva... We develop counterfactual policy learning algorithms for practical clinical applications to suggest viable treatment for patients. We first design a bootstrap method for counterfactual assessment and ... The efficacy of our algorithms was validated using both semi-synthetic and real-world clinical datasets. Our method outperforms baseline algorithms, reducing the variance in policy evaluation by 30% a... This study demonstrates the effectiveness of combining bootstrap and adversarial learning techniques in policy learning for clinical decision support. It not only enhances the accuracy and reliability...

Incorporating Expected Outcomes Into Clinical Decision-Making for Total Knee Arthroplasty.

Expected outcomes (e.g., expected survivorship after a cancer treatment) have improved decision-making around treatment options in many clinical fields. Our objective was to evaluate the effect of exp... The RAND/University of California Los Angeles appropriateness criteria method was used to evaluate the role of the 3 expected outcomes in clinical recommendation of TKA. The expected outcomes were add... Ratings for the 279 appropriateness scenarios deemed 34.4% of the scenarios as appropriate, 40.1% as inconclusive, and 25.5% as inappropriate. Classification tree analyses showed that expected improve... Our results showed that clinicians would use expected postoperative outcome factors in determining appropriateness for TKA. These results call for further work in this area to incorporate estimates of...